Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.66 USD | +3.60% | -3.55% | +94.74% |
Mar. 21 | Adverum Biotechnologies Files $200 Million Mixed Shelf | MT |
Mar. 19 | RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk | MT |
Evolution of the average Target Price on Adverum Biotechnologies, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Adverum Biotechnologies, Inc.
RBC Capital Markets | |
Mizuho Securities | |
Chardan Research | |
Ladenburg Thalmann | |
Truist Securities | |
SVB Leerink | |
Cantor Fitzgerald | |
Chardan | |
Goldman Sachs | |
UBS |
EPS Revisions
- Stock
- Equities
- Stock Adverum Biotechnologies, Inc. - Nasdaq
- Consensus Adverum Biotechnologies, Inc.